About Zona pellucida sperm-binding protein 3
Zona pellucida sperm-binding protein 3 (ZP3) is a protein
from Homo sapiens identified by UniProt accession
P21754, 424 residues long.
MolForge cross-references it against 0 known binders and
124 disease associations.
Target properties
| Protein name | Zona pellucida sperm-binding protein 3 |
| UniProt accession | P21754 |
| Gene | ZP3 |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (124)
Diseases linked to this target (Open Targets).
- female infertility due to zona pellucida defect · score 0.55
- Empty ovarian follicle · score 0.34
- triglyceride measurement · score 0.26
- lung adenocarcinoma · score 0.25
- cutaneous melanoma · score 0.25
- blood protein measurement · score 0.17
- breast adenocarcinoma · score 0.16
- glioblastoma multiforme · score 0.15
- head and neck squamous cell carcinoma · score 0.13
- cancer · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21754-F1 | alphafold | PREDICTED | 77.73 | — |
Amino-acid sequence (424 residues)
MELSYRLFIC LLLWGSTELC YPQPLWLLQG GASHPETSVQ PVLVECQEAT LMVMVSKDLF GTGKLIRAAD LTLGPEACEP LVSMDTEDVV RFEVGLHECG NSMQVTDDAL VYSTFLLHDP RPVGNLSIVR TNRAEIPIEC RYPRQGNVSS QAILPTWLPF RTTVFSEEKL TFSLRLMEEN WNAEKRSPTF HLGDAAHLQA EIHTGSHVPL RLFVDHCVAT PTPDQNASPY HTIVDFHGCL VDGLTDASSA FKVPRPGPDT LQFTVDVFHF ANDSRNMIYI TCHLKVTLAE QDPDELNKAC SFSKPSNSWF PVEGSADICQ CCNKGDCGTP SHSRRQPHVM SQWSRSASRN RRHVTEEADV TVGPLIFLDR RGDHEVEQWA LPSDTSVVLL GVGLAVVVSL TLTAVILVLT RRCRTASHPV SASE
Explore Zona pellucida sperm-binding protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets